[1] ZHANG M, ZHU X X, WU J, et al. Prevalence of hyperuricemia among Chinese adults: findings from two nationally representative cross-sectional surveys in 2015–16 and 2018–19[J]. Front Immunol, 2022, 12: 791983. doi:  10.3389/fimmu.2021.791983
[2] HASSAN W, SHRESTHA P, SUMIDA K, et al. Association of uric acid–lowering therapy with incident chronic kidney disease[J]. JAMA Netw Open, 2022, 5(6): e2215878. doi:  10.1001/jamanetworkopen.2022.15878
[3] GHANG B, PARK J, LEE J S, et al. Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy[J]. Kidney Int, 2025, 107(3): 521-529. doi:  10.1016/j.kint.2024.10.022
[4] AUBERSON M, STADELMANN S, STOUDMANN C, et al. SLC2A9(GLUT9)mediates urate reabsorption in the mouse kidney[J]. Pflügers Arch Eur J Physiol, 2018, 470(12): 1739-1751.
[5] LI L, ZHAO K L, LUO J, et al. Piperine improves hyperuricemic nephropathy by inhibiting URAT1/GLUT9 and the AKT-mTOR pathway[J]. J Agric Food Chem, 2024, 72(12): 6565-6574. doi:  10.1021/acs.jafc.3c07655
[6] SUIJK DLS, VAN BAAR MJB, VAN BOMMEL EJM, et al. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function[J]. Clin J Am Soc Nephrol, 2022, 17(5): 663-671. doi:  10.2215/CJN.11480821
[7] GIBSON T. Hyperuricemia, gout and the kidney[J]. Curr Opin Rheumatol, 2012, 24(2): 127-131. doi:  10.1097/BOR.0b013e32834f049f
[8] ZHOU J B, YANG F, ZHANG X M, et al. Jiangniaosuan formula inhibits hyperuricemia-induced apoptosis of renal tubular epithelial cells via ROS/HIF-1α/EZH2 pathway: a network pharmacology analysis and experimental validation[J]. Bioorg Chem, 2025, 159: 108363. doi:  10.1016/j.bioorg.2025.108363
[9] LI X Q, GU Y Q, LING Y Y, et al. Association between mitophagy and NLRP3 inflammasome in uric acid nephropathy[J]. Ren Fail, 2024, 46(2): 2438847. doi:  10.1080/0886022X.2024.2438847
[10] QIAN Y S, ZHANG Y, CHEN Y, et al. Linarin attenuates hyperuricemic nephropathy by modulating Nrf2/Keap1 and TLR4/NF-κB signaling pathways: Linarin attenuates hyperuricemic nephropathy[J]. Phytomedicine, 2025, 139: 156440. doi:  10.1016/j.phymed.2025.156440
[11] WU S H, YAN M X, LIU J Y, et al. Clerodendranthus spicatus inhibits epithelial-mesenchymal transition of renal tubular cells through the NF-κB/Snail signalling pathway in hyperuricaemia nephropathy[J]. Pharm Biol, 2023, 61(1): 1274-1285. doi:  10.1080/13880209.2023.2243086
[12] HELGET L N, DAVIS-KARIM A, O’DELL J R, et al. Efficacy and safety of allopurinol and febuxostat in patients with gout and CKD: subgroup analysis of the STOP gout trial[J]. Am J Kidney Dis, 2024, 84(5): 538-545. doi:  10.1053/j.ajkd.2024.04.017
[13] TERKELTAUB R. Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review[J]. Drugs, 2023, 83(16): 1501-1521. doi:  10.1007/s40265-023-01944-y
[14] YAMADA T, SAKAI Y, KURIHARA O, et al. Effect of dotinurad on serum uric acid concentration in chronic kidney disease patients treated with febuxostat[J]. J Nippon Med Sch, 2024, 91(4): 352-356. doi:  10.1272/jnms.JNMS.2024_91-403
[15] MOHAMMED A, MARIE M A, ABDULAZIM D O, et al. Serum urate lowering therapy using allopurinol improves serum 25 hydroxy vitamin D in stage 3-5 CKD patients: a pilot study[J]. Nephron, 2021, 145(2): 133-136. doi:  10.1159/000512340
[16] YANG N, CAO B. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: a double-centre, randomized, controlled study[J]. J Clin Pharm Ther, 2022, 47(12): 2214-2222. doi:  10.1111/jcpt.13794
[17] XUE X M, SUN M S, YAN F, et al. Superiority of low-dose benzbromarone add-on to low-dose febuxostat compared with febuxostat monotherapy in gout with combined-type hyperuricemia[J]. Arthritis Care Res, 2024, 76(5): 703-711.
[18] 张恩红, 崔璨. 丙磺舒联合别嘌呤醇治疗痛风间歇期临床研究[J]. 中外医疗, 2016, 35(26): 115-117. doi:  10.16662/j.cnki.1674-0742.2016.26.115
[19] OKUI D, SASAKI T, FUSHIMI M, et al. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor[J]. Clin Exp Nephrol, 2020, 24(Suppl 1): 92-102.
[20] ZHANG Y, WANG S, DAI X, et al. Simiao San alleviates hyperuricemia and kidney inflammation by inhibiting NLRP3 inflammasome and JAK2/STAT3 signaling in hyperuricemia mice[J]. J Ethnopharmacol, 2023, 312: 116530. doi:  10.1016/j.jep.2023.116530
[21] 张永琪, 陈杰伟, 叶博闻, 等. 四妙丸上调高尿酸血症大鼠小肠ABCG2表达促进肠道尿酸排泄的作用[J]. 中国实验方剂学杂志, 2022, 28(22): 33-39.
[22] 王钐, 张悦怡, 刘田园, 等. 四妙散改善高尿酸血症和肾损伤以及调节肾脏线粒体相关蛋白的作用研究[J]. 中草药, 2023, 54(13): 4177-4185. doi:  10.7501/j.issn.0253-2670.2023.13.011
[23] 张婷婷, 党翔, 杨青, 等. 痛风清利合剂通过调节尿酸转运蛋白和JAK2/STAT3信号通路缓解大鼠高尿酸血症[J]. 中国病理生理杂志, 2025, 41(5): 984-994. doi:  10.3969/j.issn.1000-4718.2025.00.014
[24] 叶文静, 杨文奎, 符芸瑜, 等. 健脾渗湿解毒汤对高尿酸血症大鼠的作用及机制探讨[J]. 中国中医基础医学杂志, 2024, 30(1): 41-45. doi:  10.19945/j.cnki.issn.1006-3250.2024.01.006
[25] 张英杰, 毛骁, 肖艳, 等. 痛风宁对高尿酸血症脾虚湿盛证模型小鼠肠道菌群及肠道尿酸代谢的影响[J]. 中医杂志, 2023, 64(21): 2232-2240. doi:  10.13288/j.11-2166/r.2023.21.012
[26] 梁天文, 胡黎平, 黄锦桃, 等. 健脾化湿泄浊方对实验性高尿酸血症大鼠肾功能及XOD活性的影响[J]. 热带医学杂志, 2017, 17(1): 5-7,19,138.
[27] ZHOU J B, WANG C X, ZHANG X M, et al. Shizhifang ameliorates pyroptosis of renal tubular epithelial cells in hyperuricemia through inhibiting NLRP3 inflammasome[J]. J Ethnopharmacol, 2023, 317: 116777. doi:  10.1016/j.jep.2023.116777
[28] LIU F F, BAI Y M, WAN Y, et al. DaiTongXiao improves gout nephropathy by inhibiting inflammatory response through the TLR4/MyD88/NF-κB pathway[J]. Front Pharmacol, 2024, 15: 1447241. doi:  10.3389/fphar.2024.1447241
[29] GONG S T, CHEN J Z, ZHENG X H, et al. Kidney targeting and modulating macrophage polarization through AMPK signaling: Therapeutic mechanism of berberine in uric acid nephropathy[J]. Int Immunopharmacol, 2024, 138: 112632. doi:  10.1016/j.intimp.2024.112632
[30] 尹智功, 肖敬, 蒋耀平, 等. 青藤碱对痛风性关节炎模型大鼠TNF-α, IL-1β及COX-2的影响[J]. 广西中医药, 2015, 38(4): 71-74.
[31] 彭佳琦, 于志豪, 王浩臻, 等. 土茯苓通过槲皮素抑制黄嘌呤氧化酶降尿酸[J]. 智慧健康, 2023, 9(11): 125-131,136. doi:  10.19335/j.cnki.2096-1219.2023.11.030
[32] PENG B Z, DAI J J, JI S, et al. Quercetin ameliorates hyperuricemic nephropathy through improving gut dysfunctions and decreasing gut bacteria-derived uremic toxins[J]. Phytomedicine, 2025, 143: 156801. doi:  10.1016/j.phymed.2025.156801
[33] SHI X L, ZHUANG L L, ZHAI Z Q, et al. Polydatin protects against gouty nephropathy by inhibiting renal tubular cell pyroptosis[J]. Int J Rheum Dis, 2023, 26(1): 116-123. doi:  10.1111/1756-185X.14463
[34] KONG X R, ZHAO L, HUANG H, et al. Isorhamnetin ameliorates hyperuricemia by regulating uric acid metabolism and alleviates renal inflammation through the PI3K/AKT/NF-κB signaling pathway[J]. Food Funct, 2025, 16(7): 2840-2856. doi:  10.1039/D4FO04867A
[35] XIE Q J, CAI X Q, DONG X, et al. Effects of epigallocatechin-3-gallate combined with ascorbic acid and glycerol on the stability and uric acid-lowering activity of epigallocatechin-3-gallate[J]. Pharm Biol, 2021, 59(1): 157-166. doi:  10.1080/13880209.2021.1878235
[36] LI X C, YAN Z X, CARLSTRÖM M, et al. Mangiferin ameliorates hyperuricemic nephropathy which is associated with downregulation of AQP2 and increased urinary uric acid excretion[J]. Front Pharmacol, 2020, 11: 49. doi:  10.3389/fphar.2020.00049
[37] ZHAO J, FU Y, QIU H B. Effect and mechanism of Plantaginis Semen polysaccharides on intestinal microecology in rats with hyperuricemia[J]. Front Microbiol, 2025, 16: 1555734. doi:  10.3389/fmicb.2025.1555734
[38] WANG L, TAO Y F, WANG X S, et al. Aqueous extract of Phellinus igniarius ameliorates hyperuricemia and renal injury in adenine/potassium oxonate-treated mice[J]. Biomed Pharmacother, 2024, 177: 116859. doi:  10.1016/j.biopha.2024.116859
[39] 靳宜静, 李堪董, 詹智晖, 等. 丹参酮ⅡA对小鼠高尿酸血症及并发心肌损伤的影响[J]. 中国组织化学与细胞化学杂志, 2024, 33(3): 232-238. doi:  10.16705/j.cnki.1004-1850.2024.03.004
[40] ZHOU X F, ZHANG B W, ZHAO X L, et al. Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis[J]. Food Funct, 2021, 12(12): 5637-5649. doi:  10.1039/D0FO03199B
[41] LAI S W, LIAO K F, KUO Y H, et al. Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia[J]. Eur J Intern Med, 2023, 113: 91-97. doi:  10.1016/j.ejim.2023.04.025